Neuronal hyperexcitability is a defining feature of numerous neurological disorders, including developmental epilepsies, drug-resistant epilepsy, and other severe neurodevelopmental conditions.
Despite major advances in neuroscience, current treatments remain largely symptomatic and are often unable to adequately control disease progression.
At Keyon Lab, we focus on Kv7 potassium channels, clinically validated regulators of neuronal excitability that play a central role in maintaining electrical stability within the nervous system. By selectively targeting these channels, we aim to restore physiological neuronal activity through innovative therapeutic approaches supported by decades of scientific research.
Our scientific platform integrates ion channel pharmacology, medicinal chemistry, computational drug discovery, and translational neuroscience to accelerate the development of novel therapies addressing significant unmet medical needs.